X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1532) 1532
Publication (76) 76
Newsletter (18) 18
Book Review (12) 12
Newspaper Article (11) 11
Book Chapter (4) 4
Magazine Article (4) 4
Web Resource (4) 4
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nebivolol (1429) 1429
humans (677) 677
male (528) 528
index medicus (441) 441
hypertension (408) 408
female (399) 399
benzopyrans - therapeutic use (348) 348
ethanolamines - therapeutic use (348) 348
hypertension - drug therapy (330) 330
middle aged (319) 319
ethanolamines - pharmacology (305) 305
benzopyrans - pharmacology (304) 304
cardiac & cardiovascular systems (296) 296
pharmacology & pharmacy (294) 294
adrenergic beta-antagonists - therapeutic use (279) 279
animals (267) 267
blood pressure - drug effects (237) 237
adrenergic beta-antagonists - pharmacology (224) 224
nitric oxide (213) 213
aged (207) 207
treatment outcome (207) 207
adult (203) 203
antihypertensive agents - therapeutic use (192) 192
carvedilol (174) 174
peripheral vascular disease (173) 173
atenolol (172) 172
rats (172) 172
beta-blockers (160) 160
metoprolol (153) 153
hypertension - physiopathology (144) 144
nitric-oxide (144) 144
benzopyrans - administration & dosage (141) 141
ethanolamines - administration & dosage (141) 141
heart failure (128) 128
oxidative stress (125) 125
blood-pressure (122) 122
heart rate - drug effects (118) 118
heart failure - drug therapy (109) 109
double-blind method (106) 106
endothelium, vascular - drug effects (105) 105
mortality (103) 103
dose-response relationship, drug (102) 102
nitric oxide - metabolism (101) 101
beta-blocker (98) 98
endothelial dysfunction (97) 97
antihypertensive agents - pharmacology (95) 95
vasodilator agents - pharmacology (91) 91
vasodilation - drug effects (87) 87
benzopyrans - adverse effects (84) 84
ethanolamines - adverse effects (84) 84
adrenergic beta-antagonists - administration & dosage (80) 80
antihypertensive agents - administration & dosage (79) 79
time factors (79) 79
vasodilator agents - therapeutic use (77) 77
blood pressure (71) 71
heart-failure (70) 70
drug therapy (68) 68
adrenergic beta-antagonists - adverse effects (67) 67
cardiovascular (67) 67
essential-hypertension (67) 67
medicine, general & internal (67) 67
prospective studies (66) 66
double-blind (65) 65
dosage and administration (61) 61
drug therapy, combination (61) 61
analysis (60) 60
endothelium (60) 60
dysfunction (59) 59
antihypertensive agents - adverse effects (58) 58
research (58) 58
medicine & public health (57) 57
nebivolol hydrochloride (57) 57
nitric-oxide synthase (57) 57
oxidative stress - drug effects (57) 57
internal medicine (56) 56
metoprolol - therapeutic use (56) 56
hypertension - complications (55) 55
endothelial-cells (54) 54
care and treatment (53) 53
hemodynamics - drug effects (53) 53
β-blockers (53) 53
adrenergic beta-1 receptor antagonists - therapeutic use (52) 52
arterial hypertension (52) 52
propanolamines - therapeutic use (52) 52
rats, wistar (52) 52
valsartan (52) 52
carbazoles - therapeutic use (51) 51
therapy (50) 50
heart failure - physiopathology (49) 49
aged, 80 and over (48) 48
forearm vasculature (48) 48
nebivolol - therapeutic use (48) 48
elderly-patients (47) 47
bisoprolol (46) 46
cardiology (46) 46
disease (46) 46
endothelium, vascular - physiopathology (46) 46
follow-up studies (46) 46
in vitro techniques (46) 46
atenolol - pharmacology (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1343) 1343
Russian (122) 122
German (46) 46
French (13) 13
Turkish (12) 12
Spanish (8) 8
Hungarian (7) 7
Italian (5) 5
Polish (4) 4
Romanian (3) 3
Korean (2) 2
Portuguese (2) 2
Ukrainian (2) 2
Chinese (1) 1
Croatian (1) 1
Japanese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 8/2015, Volume 75, Issue 12, pp. 1349 - 1371
Nebivolol is a highly selective β1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. In addition... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | BETA-BLOCKER TREATMENT | ARTERIAL-HYPERTENSION | DOUBLE-BLIND | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CENTRAL AORTIC PRESSURE | BLOOD-PRESSURE | HYPERTENSIVE PATIENTS | ERECTILE DYSFUNCTION | LEFT-VENTRICULAR FUNCTION | ELDERLY HEART-FAILURE | Drug Costs | Vasodilator Agents - pharmacokinetics | Vasodilator Agents - therapeutic use | Humans | Heart Failure - physiopathology | Hypertension - drug therapy | Nebivolol - economics | Adrenergic beta-1 Receptor Agonists - pharmacokinetics | Nebivolol - pharmacokinetics | Blood Pressure - drug effects | Heart Failure - diagnosis | Vasodilator Agents - economics | Drug Therapy, Combination | Heart Failure - economics | Hypertension - diagnosis | Hypertension - economics | Antihypertensive Agents - economics | Adrenergic beta-1 Receptor Agonists - therapeutic use | Nebivolol - therapeutic use | Treatment Outcome | Antihypertensive Agents - pharmacokinetics | Adrenergic beta-1 Receptor Agonists - economics | Antihypertensive Agents - therapeutic use | Nebivolol - adverse effects | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Heart Failure - drug therapy | Animals | Cost-Benefit Analysis | Adrenergic beta-1 Receptor Agonists - adverse effects | Vasodilator Agents - adverse effects | Heart failure | Hypertension | Nebivolol | Care and treatment | Practice guidelines (Medicine) | Dosage and administration | Management | Review
Journal Article
10/2011
Objectives: To study the effect of nebivolol 5 mg once daily versus (S)-atenolol 25 mg once daily in patients with essential hypertension. Materials and... 
Essential hypertension | nebivolol | (S)-atenolol
Web Resource
Journal of Organic Chemistry, ISSN 0022-3263, 04/2015, Volume 80, Issue 8, pp. 3965 - 3973
Journal Article
European Heart Journal, ISSN 0195-668X, 02/2005, Volume 26, Issue 3, pp. 215 - 225
Aims Large randomized trials have shown that beta-Mockers reduce mortality and hospital admissions in patients with heart failure. The effects of beta-blockers... 
Heart failure | Nebivolol | Randomized trial | Elderly | Beta-blocker | Ejection fraction
Journal Article
10/2011
Background: Nebivolol is a third-generation β-blocker, with highest β1 selectivity and nitric-oxide-derived vasodilatation. It also exhibits antiproliferative... 
nebivolol | lipid profile | blood sugar | Atenolol
Web Resource
British Journal of Clinical Pharmacology, ISSN 0306-5251, 07/2016, Volume 82, Issue 1, pp. 83 - 91
Journal Article
Journal Article
Tetrahedron: Asymmetry, ISSN 0957-4166, 09/2015, Volume 26, Issue 17, pp. 912 - 917
Chromanone-2-carboxylates and chroman-2-carboxylates are useful building blocks for the synthesis of a variety of bioactive compounds, such as repinotan,... 
CHEMISTRY, PHYSICAL | NEBIVOLOL | ACIDS | RESOLUTION
Journal Article
AMERICAN FAMILY PHYSICIAN, ISSN 0002-838X, 01/2018, Volume 97, Issue 2, pp. 124 - 125
Journal Article
Journal Article
07/2009
Nebivolol is a β-blocker that is highly selective for β1-adrenergic receptors with vasodilating properties. This property can be attributed to an endothelial... 
Nebivolol | Nitric oxide | Osteoporosis treatment | Anti-oxidant action
Web Resource
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 07/2016, Volume 311, Issue 1, pp. H118 - H124
Use of beta-adrenergic receptor (AR) blocker is associated with increased risk of fatigue and exercise intolerance. Nebivolol is a newer generation... 
Hypertension | Exercise | Sympathetic nervous system | Muscle blood flow | HUMAN FOREARM MUSCLE | RAREFACTION | NADPH OXIDASE | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | sympathetic nervous system | MIXED MEAL | SYMPATHOLYSIS | exercise | BLOOD-FLOW | HUMAN SKELETAL-MUSCLE | INSULIN | muscle blood flow | PERIPHERAL VASCULAR DISEASE | GLUCOSE-UPTAKE | hypertension | CAPILLARY RECRUITMENT | Adrenergic beta-1 Receptor Antagonists - adverse effects | Microvessels - physiopathology | Vasodilator Agents - therapeutic use | Humans | Middle Aged | NADPH Oxidases - metabolism | Hypertension - drug therapy | Male | Adrenergic beta-1 Receptor Antagonists - therapeutic use | Microcirculation - drug effects | Forearm | Ultrasonography | Female | Microvessels - enzymology | Hypertension - enzymology | Hypertension - diagnosis | Muscle Fatigue | Hand Strength | Muscle, Skeletal - blood supply | Perfusion Imaging - methods | Microvessels - drug effects | Nebivolol - therapeutic use | Metoprolol - therapeutic use | Treatment Outcome | Metoprolol - adverse effects | Antihypertensive Agents - therapeutic use | Nebivolol - adverse effects | Regional Blood Flow | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Cross-Over Studies | Muscle Contraction | Texas | Vasodilator Agents - adverse effects | Endothelial Cells - enzymology | Measurement | Nebivolol | Care and treatment | Metoprolol | Muscles | Physiological aspects | Dosage and administration | Arm | Blood flow | Index Medicus | Integrative Cardiovascular Physiology and Pathophysiology
Journal Article